ESR2 and prostate carcinoma: For example, highly selective ERβ agonists can attenuate the viability of breast cancer cell lines in vitro (43), and ERβ activation has also been observed in prostate cancer to inhibit tumor cell proliferation and suppress MYC proto-oncogene transcription (44).